deferasirox has been researched along with Pneumonia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Imoto, S; Kawano, S; Kono, M; Matsuhiroya, S; Obuchi, A; Saigo, K; Takahashi, T | 1 |
1 other study(ies) available for deferasirox and Pneumonia
| Article | Year |
|---|---|
Deferasirox, an iron-chelating agent, alleviates acute lung inflammation by inhibiting neutrophil activation and extracellular trap formation.
Topics: Animals; Chelating Agents; Deferasirox; Extracellular Traps; Inflammation; Iron; Iron Chelating Agents; Lipopolysaccharides; Lung; Male; Mice; Mice, Inbred C57BL; Neutrophil Activation; Neutrophils; Pneumonia | 2020 |